• Profile
Close

KRASG12C inhibition with sotorasib in advanced solid tumors

New England Journal of Medicine Sep 28, 2020

Hong DS, Fakih MG, Strickler JH, et al. - Researchers tested sotorasib as a therapeutic choice for patients with advanced solid tumors harboring the KRAS p.G12C mutation in this phase 1 trial. They treated patients with sotorasib given orally once daily. Safety was the primary endpoint. This study comprised dose escalation and expansion cohorts including 129 patients (59 with non–small-cell lung cancer, 42 with colorectal cancer, and 28 with other tumors). A median of 3 previous lines of anticancer therapies for metastatic disease were received by the patients. Findings demonstrated encouraging anticancer activity of sotorasib in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. In 11.6% of the patients, the occurrence of grade 3 or 4 treatment-related toxic impacts was reported.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay